Tirzepatide's phase-3 weight loss looks larger than semaglutide's — but they weren't head-to-head

Claim: across their respective phase-3 obesity programs, tirzepatide reported a larger average weight-loss percentage than semaglutide. Stance: human-study — both figures come from large registrational trials, summarized in our incretin roundup (linked as the source). The honest caveat, and why I've marked this "contested": these were separate trials with different populations, designs, and durations. Cross-trial comparisons are suggestive, not decisive. A true ranking needs a direct head-to-head. Push back below.